Serum autoantibodies against hexokinase 1 manifest secondary to
diabetic macular edema onset

J 2024

Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset

ŠIMČÍKOVÁ, Daniela; Jana IVANČINOVÁ; Miroslav VEITH; Jaroslava DUSOVÁ; Veronika MATUŠKOVÁ et al.

Základní údaje

Originální název

Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset

Autoři

Vydání

Diabetes Research and Clinical Practice, CLARE, ELSEVIER IRELAND LTD, 2024, 0168-8227

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30207 Ophthalmology

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.400

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00136124

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Autoimmunity; Glycolysis; Disease marker; Disease prediction; Tissue damage; Vitreous fluid

Štítky

14110219, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 8. 2024 13:37, Mgr. Tereza Miškechová

Anotace

V originále

Aims Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset. Materials and methods Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies. Results Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME. Conclusions Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.

Citovat

ŠIMČÍKOVÁ, Daniela; Jana IVANČINOVÁ; Miroslav VEITH; Jaroslava DUSOVÁ; Veronika MATUŠKOVÁ; Jan NĚMČANSKÝ; Přemysl KUNČICKÝ; Oldřich CHRAPEK; Naďa JIRÁSKOVÁ; Jan GOJDA a Petr HENEBERG. Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset. Diabetes Research and Clinical Practice. CLARE: ELSEVIER IRELAND LTD, 2024, roč. 212, June 2024, s. 1-9. ISSN 0168-8227. Dostupné z: https://doi.org/10.1016/j.diabres.2024.111721.

@article{2407820,
   author = {Šimčíková, Daniela and Ivančinová, Jana and Veith, Miroslav and Dusová, Jaroslava and Matušková, Veronika and Němčanský, Jan and Kunčický, Přemysl and Chrapek, Oldřich and Jirásková, Naďa and Gojda, Jan and Heneberg, Petr},
   article_location = {CLARE},
   article_number = {June 2024},
   doi = {https://doi.org/10.1016/j.diabres.2024.111721},
   keywords = {Autoimmunity; Glycolysis; Disease marker; Disease prediction; Tissue damage; Vitreous fluid},
   language = {eng},
   issn = {0168-8227},
   journal = {Diabetes Research and Clinical Practice},
   title = {Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset},
   url = {https://www.sciencedirect.com/science/article/pii/S0168822724006314?via%3Dihub},
   volume = {212},
   year = {2024}
}

TY  - JOUR
ID  - 2407820
AU  - Šimčíková, Daniela - Ivančinová, Jana - Veith, Miroslav - Dusová, Jaroslava - Matušková, Veronika - Němčanský, Jan - Kunčický, Přemysl - Chrapek, Oldřich - Jirásková, Naďa - Gojda, Jan - Heneberg, Petr
PY  - 2024
TI  - Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset
JF  - Diabetes Research and Clinical Practice
VL  - 212
IS  - June 2024
SP  - 1-9
EP  - 1-9
PB  - ELSEVIER IRELAND LTD
SN  - 01688227
KW  - Autoimmunity
KW  - Glycolysis
KW  - Disease marker
KW  - Disease prediction
KW  - Tissue damage
KW  - Vitreous fluid
UR  - https://www.sciencedirect.com/science/article/pii/S0168822724006314?via%3Dihub
N2  - Aims Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset. Materials and methods Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies. Results Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME. Conclusions Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.
ER  -

ŠIMČÍKOVÁ, Daniela; Jana IVANČINOVÁ; Miroslav VEITH; Jaroslava DUSOVÁ; Veronika MATUŠKOVÁ; Jan NĚMČANSKÝ; Přemysl KUNČICKÝ; Oldřich CHRAPEK; Naďa JIRÁSKOVÁ; Jan GOJDA a Petr HENEBERG. Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset. \textit{Diabetes Research and Clinical Practice}. CLARE: ELSEVIER IRELAND LTD, 2024, roč.~212, June 2024, s.~1-9. ISSN~0168-8227. Dostupné z: https://doi.org/10.1016/j.diabres.2024.111721.

Přehled o publikaci